Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: TMO stock price vs BSX: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at BSX's multiple
Needs BSX P/E.
Implied fair value · at TMO's multiple
Needs TMO P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Nine period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
THERMO FISHER SCIENTIFIC INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
BOSTON SCIENTIFIC CORPORATION · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Agilent Technologies, Inc.
TMO vs A
DANAHER CORP /DE/
TMO vs DHR
Illumina, Inc.
TMO vs ILMN
BRUKER CORP
TMO vs BRKR
Abbott Laboratories
TMO vs ABT
Johnson & Johnson
TMO vs JNJ
Intuitive Surgical, Inc.
TMO vs ISRG
STRYKER CORP
TMO vs SYK
ZIMMER BIOMET HOLDINGS, INC.
TMO vs ZBH
Edwards Lifesciences Corp
TMO vs EW
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe TMO can reaccelerate growth and sustain its stronger ROIC and leverage profile, then hold or accumulate on weakness because the current valuation already prices in a premium to BSX and implies downside to BSX-based fair value.
TMO's current price of $580.02 sits above BSX-implied range of $427.24-$460.76 and below the top of its historical band at $638.02, implying the stock trades rich to BSX but not outside its own recent trading history. The -22.3% implied downside versus the P/E-derived fair value of $450.82 reflects a valuation gap driven by TMO's higher P/E, P/S, EV/EBITDA, and EV/Revenue multiples versus BSX.
Supporting Metrics
